Head and Neck Squamous Cell Carcinoma (HNSC)

Overview

Head and neck squamous cell carcinoma (HNSC) encompasses squamous cell carcinomas arising in the oral cavity, oropharynx, larynx, and hypopharynx. HPV status is a major determinant of biology and prognosis. Standard-of-care includes concurrent chemoradiation (RT + cisplatin); recurrent and second-primary disease represent major clinical challenges. Resistance to both chemotherapy and immunotherapy remains incompletely characterized.

Cohorts in the corpus

  • ROBIN GenRad HNSCC MCT (NCT03521570, GenRad part B; Cleveland Clinic and Emory University) — completed trial of RT + cisplatin vs. RT + immune checkpoint inhibitor in HNSCC; results published for the recurrent/second-primary arm. PMID:41941260
  • Javelin HN100 expansion cohort (chemoradiation ± avelumab) — analyzed by the GenRad team to characterize tumor mutations and microenvironmental resistance factors. PMID:41941260
  • NCT03521570 (MIRI-based reirradiation + nivolumab): 51 evaluable patients with recurrent or second primary HNSC in a previously irradiated field (≥40 Gy); sites: oral cavity 31%, oropharynx 27%, larynx/hypopharynx 25%, nasopharynx 12%; p16-positive 12%, p16-negative 18%. Multicenter (Emory/Winship, Cleveland Clinic, Medical College of Wisconsin). PMID:38780927
  • CAL-27 and SCC-25 (EGFR+, HNSC cell lines); SCC-35, SCC-61, SQ-9G (HNSC, EGFR+): preclinical ADC radiosensitization study. PMID:27698471
  • Aerts 2014 foundational CT radiomics study included two HN cohorts: HN1 (n=136, MAASTRO Clinic, oropharyngeal/oral cavity) and HN2 (n=95, VUmc Amsterdam, HNSCC), with the 4-feature radiomic signature validated for overall survival prediction in these cohorts PMID:24892406.
  • Grossberg 2018 published the MD Anderson Head and Neck Quantitative Imaging Working Group archive (n=697 HNSCC patients) pairing pre-treatment CT/PET imaging with clinical outcomes, enabling radiomics and dose-response analyses PMID:30179230.
  • Welch 2024 published RADCURE, a large multi-institutional HNSCC imaging dataset (n=3,346 patients from Princess Margaret Cancer Centre) with CT scans and clinical outcome data for radiomics model development and benchmarking PMID:38362943.
  • RADCURE internal-challenge cohort (Princess Margaret Cancer Centre, 2005–2017): 2,552 HNSC patients treated with definitive radiotherapy/chemoradiotherapy; training set n=1,802, held-out test n=750. Three external validation cohorts totaling 873 patients: HN1 (n=137, MAASTRO), MDACC / tcia-hnscc (n=627, MD Anderson), GPCCHN / gpcchn-poznan (n=298, Greater Poland Cancer Centre). Primary task: 2-year OS from pretreatment CT + EMR. PMID:37397861

Recurrent alterations

No gene-level variant frequencies are reported in the corpus for HNSC; studies focus on immune and microenvironmental dynamics.

  • Intratumoral bacteria identified as a major source of therapy resistance in HNSC patients receiving chemoradiation-immunotherapy combinations (Javelin HN100 expansion cohort). PMID:41941260
  • PD1+Ki67+CD4+ T-cell expansion of ≥1.5-fold from baseline to week 2–4 of treatment was associated with shorter progression-free survival under intensity-modulated re-irradiation + PD-1 blockade. PMID:41941260
  • CD274 (PD-L1) CPS <20 vs. ≥20 (22C3 pharmDx IHC) did not predict PFS or OS benefit in the reirradiation + nivolumab context (68.8% vs. 59.2% 1-year PFS, P=.86), unlike in recurrent/metastatic HNSCC with single-agent PD-1 blockade. PMID:38780927
  • EGFR surface expression (not mutation status) gates C-MMAE binding and radiosensitization in HNSC cell lines (CAL-27, SCC-61, SCC-35, SQ-9G). PMID:27698471
  • Prognostic modeling study (RADCURE challenge): no gene-level alteration frequencies reported; HPV status used as a categorical EMR feature (positive / negative / not tested) rather than a molecular endpoint. EMR features including HPV status outperformed all CT-radiomics models for 2-year OS prediction (winning MTLR model AUROC = 0.823 on internal test). PMID:37397861
  • HNSC genomic data made available through the cBioPortal for Cancer Genomics platform, enabling interactive exploration of somatic alterations PMID:19176454
  • Whole-exome sequencing of 74 HNSCC tumors identified NOTCH1, TP53, and CDKN2A as top drivers, with NOTCH1 mutated in ~15% of cases PMID:21798893
  • Whole-exome sequencing of 32 primary HNSCC tumors (JHU) identified recurrent NOTCH1 inactivating mutations as a major driver event PMID:21798897
  • Multi-platform genomic analysis of 40 OSCC (an HNSC subtype) identified four major driver pathways (mitogenic signaling 63%, Notch 66%, cell cycle 94%, TP53 60%), novel FAT1 inactivation in 46% and CASP8 mutations in 10% defining a CN-quiet subtype; 80% of tumors harbored at least one targetable alteration PMID:23619168
  • RHOA E40Q fails to complement yeast RHO1 (no viable colonies on 5-FOA) and recurs in solid tumours including head-and-neck squamous cell carcinoma PMID:24816253
  • Narrative review of R/M NPC therapeutics notes EGFR overexpression in a substantial fraction of NPC (a head-and-neck malignancy); NPC-specific agents are catalogued but HNSC more broadly is referenced in the EBV-negative squamous carcinoma context PMID:24952746
  • TCGA multi-platform profiling of 279 HNSC defined two non-overlapping biologies: HPV(+) tumours with TRAF3 loss (14%), PIK3CA helical-domain mutations (56%), and E2F1 amplification; HPV(−) tumours with TP53 mutation (86%), CDKN2A loss, and 11q13/22 co-amplification. Eleven significantly mutated genes identified (MutSigCV q<0.1); candidate therapeutic alterations present in most tumours. PMID:25631445
  • Morris et al. (MSK, N=151 advanced/recurrent head and neck tumors, MSK-IMPACT 410-gene panel) found that NGS guided therapy in 13/53 (25%) of HNSC patients; TERT promoter mutations in 16/30 (53%) HPV-negative recurrent/metastatic HNSC versus 12/70 (17%) primary HPV-negative tumors (OR 5.5, P<.001); 43% of advanced HPV-positive tumors acquired an HPV-negative-like genotype associated with worse survival PMID:27442865.
  • TCGA comparison: ESCC1 and ESCC2 gene expression profiles closely resemble TCGA head and neck squamous cell carcinoma (HNSCC) classical and basal subtypes respectively; ESCC3 (SMARCA4-mutant, US/Canada only) has no analogue in the TCGA HNSCC dataset PMID:28052061
  • TCGA HNSC mutational signatures were used as a reference comparison in the first WES landscape of vulvar squamous cell carcinoma; open question remains whether the 40% PIK3CA and FAT1 prevalences in vulvar SCC align with rates in HNSC and other head-and-neck SCCs PMID:29422544
  • MC3 pan-cancer mutation-calling project (10,510 TCGA pairs) included HNSC; HNSC concordance with the legacy PanCan12 MAF exceeded 90% PMID:29596782
  • Pan-cancer fusion study (9,624 TCGA samples) identified a TRABD–DDR2 promoter-swap fusion driving DDR2 overexpression in one HNSC sample (candidate for dasatinib); DDR2 fusions seen in nine additional samples across five cancer types; FGFR3–TACC3 was present in 1.2% of LUSC (squamous) tumors PMID:29617662
  • Pan-cancer aneuploidy study placed HPV+ and HPV− HNSC in the squamous arm-level cluster (chr_3p loss + chr_3q gain); the squamous signature was strongest in LUSC, ESCC, and HPV-negative HNSC; leukocyte fraction was negatively correlated with aneuploidy in HNSC (Spearman ρ = −0.312) PMID:29622463

Subtypes

No molecular subtype breakdown in the corpus for HNSC beyond HPV context implied by the trial populations.

  • In NCT03521570, p16/HPV-positive patients represented only 12% of evaluable patients; the trial was not powered for subgroup analyses by HPV status. PMID:38780927
  • RADCURE challenge cohort had significant HPV status distribution shift vs. external validation cohorts (pairwise χ² FDR ≤ 5%); GPCCHN (Poznań) had disproportionately more HPV-negative patients, contributing to external model performance drops. PMID:37397861

Therapeutic landscape

  • ROBIN GenRad center (U54 CA274513; Cleveland Clinic and Emory University) tested intensity-modulated re-irradiation + PD-1 inhibition in recurrent or second-primary HNSC (NCT03521570): the combination was tolerable and effective in a subset of patients; shorter PFS was associated with a ≥1.5-fold increase in PD1+Ki67+CD4+ T cells at week 2–4, identifying a candidate resistance biomarker. PMID:41941260
  • Javelin HN100 expansion cohort analysis (chemoradiation ± avelumab) identified intratumoral bacteria as a major resistance mechanism to chemoradiation-immunotherapy in HNSC — flagged as a potentially druggable axis. PMID:41941260
  • GenRad is leveraging longitudinal genomics and proteomic data from HNSCC MCT patients to characterize transcriptional dynamics and temporal reprogramming during RT + cisplatin vs. RT + ICI treatment to identify biomarkers of sensitivity and resistance. PMID:41941260
  • IMRT-based reirradiation + concurrent/maintenance nivolumab in recurrent/second-primary HNSC (NCT03521570): 1-year PFS 61.7% (95% CI 49.2%–77.4%, 1-arm log-rank P=.002 vs. historical null of 43.8%), median PFS 20.7 months, median OS 21 months (2-year OS 48.4%). Grade ≥3 treatment-related adverse events in 11.8%; no grade 5 events. FACT-G/FACT-H&N quality-of-life scores stable through 104 weeks. PMID:38780927
  • In HNSC xenograft (CAL-27, EGFR+), C-MMAE (cetuximab–MMAE ADC) + IR produced significantly greater tumor-growth delay than free MMAE or cetuximab alone (P<0.0001 by day 35), establishing EGFR-directed ADC radiosensitization as a selective strategy. PMID:27698471
  • RADCURE crowdsourced ML challenge (Princess Margaret): multitask logistic regression (MTLR) on EMR features + primary tumor volume was the top prognostic model for 2-year OS (AUROC 0.823, C-index 0.801, HR 8.64 for high- vs. low-risk groups). Deep-learning CT radiomics did not improve over EMR-only models when combined; standalone CT radiomics did not outperform any EMR model. External generalizability was limited (performance drop in 2 of 3 external cohorts), with distribution shift in HPV status and disease site as primary drivers. PMID:37397861

Sources

This page was processed by crosslinker on 2026-05-14. - PMID:24816253

This page was processed by crosslinker on 2026-05-14. - PMID:24952746

This page was processed by crosslinker on 2026-05-14. - PMID:25631445

This page was processed by crosslinker on 2026-05-14. - PMID:27442865 — Morris et al. 2017 (JAMA Oncol). MSK-IMPACT of 151 advanced head and neck tumors; NGS guided therapy in 25% of HNSC patients.

This page was processed by entity-page-writer on 2026-05-15. - PMID:28052061

This page was processed by wiki-cli on 2026-05-14. - PMID:29422544

This page was processed by entity-page-writer on 2026-05-15. - PMID:29596782

This page was processed by wiki-cli on 2026-05-15. - PMID:29617662

This page was processed by wiki-cli on 2026-05-15. - PMID:29622463

This page was processed by wiki-cli on 2026-05-15.